Actavis Can't Sell Generic Gralise After Depomed IP Trial

By Beth Winegarner (August 25, 2014, 8:48 PM EDT) -- Actavis Elizabeth LLC is barred from producing and selling a generic version of timed-release Gralise after a New Jersey federal judge found that Actavis infringed several Depomed Inc. patents on the neuropathic pain medication, according to a ruling unsealed Monday following a seven-day bench trial in May....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!